Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation
....
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013501/
Hydroxychloroquine treatment is common place in SLE, as it reduces relapse rates and the risk of thrombotic events,31 and in experimental lupus models, the drug has been found to reduce endothelial dysfunction.14 42 We did not find a significant effect of sustained hydroxychloroquine therapy on of VWF levels or platelet aggregation activity in our cohort, suggesting that hydroxychloroquine exerts its vasoprotective effects through other pathways. Similarly, we were unable to detect an effect of antiphosphol
George Tzoras
7 hours ago
Medcram what about if the destruction of endothelial cells leads to exposure of the subendothelial collagen and tissue factor? So coagulation occurs due to both increased vWF and exposure of SEC.